These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20944900)

  • 1. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Mitsuzuka K; Arai Y
    Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Patil T; Bernard B
    Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
    Miller K
    Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG; Canfield SE; Du XL
    Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.